Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 120M | 111M | 117M | 139M | 140M |
| Gross Profit | 41M | 50M | 46M | 54M | 53M |
| Operating Income | 12M | 9M | -47M | 7M | 4M |
| EBITDA | 29M | 25M | -31M | 21M | 20M |
| Net Income | 11M | 8M | -49M | 5M | 3M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$19.43
-1.87% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
CareCloud, Inc. (CCLDP) is a Healthcare stock with a market cap of $59.88M. The stock last traded around $19.43. Baseline metrics include revenue growth of +8.7%, EPS growth of +135.7%, a dividend yield of 0.0%. What stands out right now is revenue +8.7%, EPS +135.7%, free cash flow +25.5% with operating margin 9.5% and ROIC 17.4%. Valuation already assumes a fairly strong business story at P/E 102.5 and price/sales 1.0. Stock Foundry combines CCLDP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
CCLDP
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
CCLDP Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CCLDP and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$139.6M
+0.6% YoY
FY Net Income
$2.8M
-47.8% YoY
Free Cash Flow
$2.8M
-70.5% YoY
Revenue Growth
+8.7%
EPS Growth
+135.7%
Gross Margin
34.1%
Net Margin
9.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 120M | 111M | 117M | 139M | 140M |
| Gross Profit | 41M | 50M | 46M | 54M | 53M |
| Operating Income | 12M | 9M | -47M | 7M | 4M |
| EBITDA | 29M | 25M | -31M | 21M | 20M |
| Net Income | 11M | 8M | -49M | 5M | 3M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 3M | 5M | 3M | 12M | 9M |
| Total Assets | 88M | 72M | 78M | 136M | 141M |
| Total Liabilities | 28M | 22M | 36M | 34M | 43M |
| Shareholder Equity | 60M | 50M | 42M | 102M | 98M |
| Total Debt | 4M | 3M | 15M | 14M | 17M |
| Net Debt | 1M | -2M | 11M | 2M | 8M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
13M
-37.0% YoY
Capital Expenditures
11M
+10.2% YoY
Free Cash Flow
3M
-70.5% YoY
Key ratios
Gross Margin
34.1%
Operating Margin
9.5%
Net Margin
9.0%
ROE
19.0%
Debt / Equity
0.07x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.